Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report
ABSTRACT The mesenchymal‐epithelial transition factor (MET) Y1003 mutation, like MET ex14 skipping, is an oncogenic driver mutation that suppresses MET degradation. Herein, we report the case of a 63‐year‐old female patient with lung adenocarcinoma harboring the MET Y1003N mutation, who was treated...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15508 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576741809324032 |
|---|---|
| author | Yukihiro Umeda Satomi Kimura Junya Kimura Yoshiaki Imamura Tamotsu Ishizuka |
| author_facet | Yukihiro Umeda Satomi Kimura Junya Kimura Yoshiaki Imamura Tamotsu Ishizuka |
| author_sort | Yukihiro Umeda |
| collection | DOAJ |
| description | ABSTRACT The mesenchymal‐epithelial transition factor (MET) Y1003 mutation, like MET ex14 skipping, is an oncogenic driver mutation that suppresses MET degradation. Herein, we report the case of a 63‐year‐old female patient with lung adenocarcinoma harboring the MET Y1003N mutation, who was treated with tepotinib, a selective type 1b MET tyrosine kinase inhibitor. To the best of our knowledge, no such cases have been reported. The woman was referred to our hospital with the chief complaint of chest pain. After a detailed examination, she was diagnosed with stage IVB lung adenocarcinoma. Next‐generation sequencing revealed an MET Y1003N mutation in the tumor. Tepotinib was administered as the eighth‐line treatment, and the best overall response was a partial response that lasted for 8 months. In lung adenocarcinomas harboring the MET Y1003 mutation, selective type 1b MET tyrosine kinase inhibitors may be an important treatment option, even in heavily pretreated settings. |
| format | Article |
| id | doaj-art-236a0c21fc9a48c9a0f57cee0b0eae0b |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-236a0c21fc9a48c9a0f57cee0b0eae0b2025-01-30T22:40:34ZengWileyThoracic Cancer1759-77061759-77142025-01-01162n/an/a10.1111/1759-7714.15508Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case ReportYukihiro Umeda0Satomi Kimura1Junya Kimura2Yoshiaki Imamura3Tamotsu Ishizuka4Department of Respiratory Medicine Faculty of Medical Sciences, University of Fukui Eiheiji Fukui JapanDepartment of Respiratory Medicine Faculty of Medical Sciences, University of Fukui Eiheiji Fukui JapanDivision of Diagnostic Pathology/Surgical Pathology University of Fukui Hospital Eiheiji Fukui JapanDivision of Diagnostic Pathology/Surgical Pathology University of Fukui Hospital Eiheiji Fukui JapanDepartment of Respiratory Medicine Faculty of Medical Sciences, University of Fukui Eiheiji Fukui JapanABSTRACT The mesenchymal‐epithelial transition factor (MET) Y1003 mutation, like MET ex14 skipping, is an oncogenic driver mutation that suppresses MET degradation. Herein, we report the case of a 63‐year‐old female patient with lung adenocarcinoma harboring the MET Y1003N mutation, who was treated with tepotinib, a selective type 1b MET tyrosine kinase inhibitor. To the best of our knowledge, no such cases have been reported. The woman was referred to our hospital with the chief complaint of chest pain. After a detailed examination, she was diagnosed with stage IVB lung adenocarcinoma. Next‐generation sequencing revealed an MET Y1003N mutation in the tumor. Tepotinib was administered as the eighth‐line treatment, and the best overall response was a partial response that lasted for 8 months. In lung adenocarcinomas harboring the MET Y1003 mutation, selective type 1b MET tyrosine kinase inhibitors may be an important treatment option, even in heavily pretreated settings.https://doi.org/10.1111/1759-7714.15508adenocarcinoma of lungsMET Y1003mutationtepotinibtyrosine kinase inhibitors |
| spellingShingle | Yukihiro Umeda Satomi Kimura Junya Kimura Yoshiaki Imamura Tamotsu Ishizuka Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report Thoracic Cancer adenocarcinoma of lungs MET Y1003 mutation tepotinib tyrosine kinase inhibitors |
| title | Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report |
| title_full | Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report |
| title_fullStr | Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report |
| title_full_unstemmed | Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report |
| title_short | Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report |
| title_sort | tepotinib for the treatment of lung adenocarcinoma harboring met y1003n point mutation a case report |
| topic | adenocarcinoma of lungs MET Y1003 mutation tepotinib tyrosine kinase inhibitors |
| url | https://doi.org/10.1111/1759-7714.15508 |
| work_keys_str_mv | AT yukihiroumeda tepotinibforthetreatmentoflungadenocarcinomaharboringmety1003npointmutationacasereport AT satomikimura tepotinibforthetreatmentoflungadenocarcinomaharboringmety1003npointmutationacasereport AT junyakimura tepotinibforthetreatmentoflungadenocarcinomaharboringmety1003npointmutationacasereport AT yoshiakiimamura tepotinibforthetreatmentoflungadenocarcinomaharboringmety1003npointmutationacasereport AT tamotsuishizuka tepotinibforthetreatmentoflungadenocarcinomaharboringmety1003npointmutationacasereport |